Please upgrade your browser.
Emergency department visits, including those that resulted in hospital admissions, grew an average 4 percent every year from 2010 to 2016.
KEYNOTE-427 is a single-arm, open-label, non-randomized, multi-cohort, Phase 2 study evaluating the safety and efficacy of KEYTRUDA as monotherapy in patients with advanced RCC who have not received prior systemic therapy.
To evaluate trends in the use of partial nephrectomy in the United States, researchers collected information about more than 48,000 patients with non-metastatic kidney cancer treated between 1998 and 2007.
The Kidney Cancer Association has announced the winners of its annual Young Investigator Award (YIA). The award provides funding to promising doctors to pursue careers in kidney cancer research.
The approvals were based on CheckMate 214 (NCT02231749), a randomized open-label trial. Patients with previously untreated advanced RCC received nivolumab (3 mg/kg) plus ipilimumab (1 mg/kg) every 3 weeks for 4 doses followed by nivolumab monotherapy (3 mg/kg) every 2 weeks, or sunitinib 50 mg daily for 4 weeks followed by 2 weeks off every cycle.
A single damaged cell may be all it takes to trigger aggressive and terminal kidney cancer almost a lifetime after the first step towards the disease is taken.
Lead study author Aaron Mitchell said they also found prescriptions increased as the amount of money physicians received went up. Payments for research, by contrast, were not associated with statistically significant differences in prescribing.
A new technology has shown promise in treating several types of tumors in mice that do not respond to cancer immunotherapy medications called checkpoint inhibitors.
Renal cell carcinoma (RCC) is the most common form of kidney cancer, with an estimated 65,340 patients expected to be diagnosed in 2018 in the United States alone. Nearly a third of those patients will be diagnosed with the advanced or metastatic disease.
Nivolumab plus ipilimumab improved OS and objective response rates compared with sunitinib among patients with intermediate- and poor-risk advanced renal-cell carcinoma, according to findings published in The New England Journal of Medicine.
|Powered by NeonCRM|